SN Bioscience doses first patient in global trial of experimental drug for aggressive lung cancer
The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients
The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients
The company reported free cash flow of Rs. 2,590 Mn for FY26
The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index
Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
The global diagnostics supplier said the multi-phase expansion aims to deliver more than 60 commercially available recombinant antigen products by 2030
Baxfendy works in a fundamentally different way from current therapies
Access to genomic testing, not therapy cost, is the biggest challenge
Company enters women’s personal grooming segment while strengthening pain management portfolio with herbal Ortho Oil
Subscribe To Our Newsletter & Stay Updated